Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03257410
Other study ID # 7905001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 29, 2017
Est. completion date October 27, 2018

Study information

Verified date January 2021
Source Baxter Healthcare Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study evaluates the efficacy and safety of the Theranova 400 dialyzer compared with Elisio-17 H dialyzer in end stage renal disease patients receiving hemodialysis treatment. Efficacy will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. Safety will be evaluated by maintaining pre-dialysis serum albumin levels and other safety events including laboratory tests and adverse events. Patients will undergo 3 dialysis sessions per week, for 24 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 172
Est. completion date October 27, 2018
Est. primary completion date October 27, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ESRD patients age 22 and older, or between ages 18 and 21 with a weight = 40kg. - Clinically stable as judged by the treating physician and as demonstrated by stable medical history for 30 days prior to enrollment, physical examination, and laboratory testing. - Hemodialysis therapy with high-flux dialyzers for at least 3 months immediately prior to study enrollment and expected to survive for the next 12 months. - Expected to maintain an acceptable urea clearance (Kt/V) with a dialyzer of an approximate surface area of 1.7 m2. - Currently being dialyzed at an in-center setting, on a schedule of 3 times per week. - Able to give informed consent after an explanation of the proposed study, and who are willing to comply with the study requirements for therapy during the entire study treatment period. - Have a stable functioning vascular access (arteriovenous fistula, graft, or dual lumen tunneled catheter); stable access will be confirmed by observed Kt/V >= 1.2 for past 2 measurements, and/or achievement of within 15% the prescribed blood flow rate over 3 treatments prior to study entry. Exclusion Criteria: - Are female and pregnant, lactating, or planning to become pregnant during the study period. Note: Female subjects of childbearing potential, defined as a woman <55 years old who has not had a partial or full hysterectomy or oophorectomy, must have a negative serum beta human chorionic gonadotropin (ß-hCG) pregnancy test at screening. Subjects of childbearing potential must use a medically acceptable means of contraception during their participation in the study. - Have chronic liver disease. - Have a known paraprotein-associated disease. - Have known bleeding disorders (e.g., gastrointestinal bleed, colonic polyps, small bowel angiodysplasia, and active peptic ulcers). - Have had a major bleeding episode (i.e. soft tissue bleeding, blood in stool, prolonged nose bleeds, joint damage, retinal bleeding, extensive mucosal bleeding, exsanguination, cerebral hemorrhage) = 12 weeks prior to randomization. - Have had a blood (red blood cell) transfusion = 12 weeks prior to randomization. - Have had an acute infection = 4 weeks prior to randomization. - Have active cancer, except for basal cell or squamous cell skin cancer. - Have a known serum ?/? FLC ratio that is less than 0.37, or greater than 3.1.b - Have a known monoclonal gammopathy (monoclonal gammopathy of uncertain significance, smoldering [asymptomatic] multiple myeloma, symptomatic multiple myeloma, plasmacytomas, or plasma cell leukemia). - Have a known polyclonal gammopathy (connective tissue disease, liver disease, chronic infection, lymphoproliferative disorder, or other hematologic condition). - Have a positive serology test for human immunodeficiency virus or hepatitis infection. - Have a significant psychiatric disorder or mental disability. - Are scheduled for planned interventions requiring hospitalization > 1 week. - Are scheduled for living-donor transplantation within the study period + 3 months, plan to change to PD therapy within the next 9 months, plan to change to a home hemodialysis treatment, or plan to relocate to an area where no study center is located. - Are currently participating in another interventional clinical study or has participated in another interventional clinical study in the past 3 months. - Have a history of non-compliance with HD as assessed by an investigator. - Have had a major cardiovascular or cerebrovascular event within 3 months of study entry. - Have a history with consistent evidence of intradialytic hypotension. - Have uncontrolled (systolic BP > 180 mmHg) hypertension. - Have had adverse reactions to dialyzer materials.

Study Design


Intervention

Device:
Theranova 400 dialyzer
Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.
Elisio-17H dialyzer
Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.

Locations

Country Name City State
United States Dialysis Center, Inc. Albany Albany Georgia
United States Dialysis Center, Inc. Kidney Associates of Kansas City Belton Missouri
United States DaVita Inc, Greater Hartford Nephrology Bloomfield Connecticut
United States Dialysis Center, Inc. Boston Boston Massachusetts
United States DaVita Inc., Bronx Dialysis Center Bronx New York
United States DaVita Inc., Norfolk Dialysis Chesapeake Virginia
United States DaVita Corona Corona California
United States DaVita Inc., Transmountain Dialysis El Paso Texas
United States DaVita Inc., Medical Center Dialysis Houston Texas
United States Dialysis Center, Inc. Holston River Clinic Knoxville Tennessee
United States DaVita Five Star Dialysis Center Las Vegas Nevada
United States DaVita Inc., South Las Vegas Dialysis Las Vegas Nevada
United States DaVita Renal Center of Lewisville Lewisville Texas
United States Dialysis Center of Lincoln Lincoln Nebraska
United States DaVita Inc., Waterbury Dialysis Middlebury Connecticut
United States Dialysis Center, Inc. North Brunswick North Brunswick New Jersey
United States Dialysis Center, Inc. Philidelphia Philadelphia Pennsylvania
United States DaVita Riverside Riverside California
United States DaVita Floyd Curl Dialysis San Antonio Texas
United States DaVita Inc., Northwest Medical Center Dialysis San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Baxter Healthcare Corporation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Weiner DE, Falzon L, Skoufos L, Bernardo A, Beck W, Xiao M, Tran H. Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1310-1319. doi: 10.2215/CJN.01210120. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 FLC=free light chains Week 24
Primary Pre-dialysis Serum Level of Albumin at Week 24 Week 24
Secondary Reduction Ratio of Lambda Immunoglobulin FLC at Week 4 and Week 24 FLC=free light chains Week 4 and Week 24
Secondary Reduction Ratio of Complement Factor D CFD=complement factor D Week 4 and 24
Secondary Reduction Ratio of ? FLC ? FLC = Kappa Free light chains Week 4 and 24
Secondary Reduction Ratio of Interleukin 6 IL-6=interleukin 6 Week 4 and 24
Secondary Reduction Ratio of Tumor Necrosis Factor Alpha TNFa=tumor necrosis factor alpha Week 4 and 24
Secondary Reduction Ratio of ß2-microglobulin ß2=beta 2 Week 4 and 24
Secondary Change From Baseline in Pre-dialysis ß2-microglobulin at Week 24 Baseline, Week 24
Secondary Kt/Vurea Kt/Vurea = Dimensionless number used to quantify hemodialysis and peritoneal dialysis adequacy. Week 4, 8, 12, 16, 20, 24
Secondary Change From Baseline in Pre-dialysis Serum Albumin by Visit Baseline, Week 4, 8, 12, 16, 20, 24
Secondary Change From Baseline in Pre-dialysis Factor VII by Visit Baseline, Week 12, Week 24
Secondary Change From Baseline in Pre-dialysis Protein C by Visit Baseline, Week 12, Week 24
Secondary Change From Baseline in Pre-dialysis Vitamin A by Visit Baseline, Week 4, Week 24
Secondary nPNA (nPCR) nPNA=normalized Protein equivalent of Nitrogen Appearance, and nPCR=normalized Protein Catabolic Rate. Week 4, 8, 12, 16, 20, 24
Secondary Change From Baseline in Pre-dialysis Factor II by Visit Factor II (Prothrombin) Baseline, Week 12, Week 24
Secondary Change From Baseline in Sodium (mmol/L) at End of Study (up to Week 24) Baseline and Week 24
Secondary Change From Baseline in Potassium (mmol/L) at End of Study (up to Week 24) Baseline and Week 24
Secondary Change From Baseline in Calcium (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Phosphate (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Chloride (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Bicarbonate (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Glucose (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Prothrombin Time (Sec) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Prothrombin Intl. Normalized Ratio at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Activated Partial Thromboplastin Time (Sec) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Hematocrit (L/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Hemoglobin (g/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin (pg) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Erythrocyte Mean Corpuscular HGB Concentration (g/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Erythrocyte Mean Corpuscular Volume (fL) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Platelets at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Erythrocytes at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Leukocytes at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Basophils (%) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Eosinophils (%) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Lymphocytes (%) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Monocytes (%) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Neutrophils (%) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Pre-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Post-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in BUN Reduction Ratio at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Creatinine (µmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Kt/Vurea by Visit Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Secondary Change From Baseline in Vitamin A (µmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Cholesterol (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in HDL Cholesterol (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in LDL Cholesterol (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Triglycerides (mmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Alkaline Phosphatase (U/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Alanine Aminotransferase (U/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Aspartate Aminotransferase (U/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Direct Bilirubin (µmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Bilirubin (µmol/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Gamma Glutamyl Transferase (U/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Protein (g/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Globulin (g/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in High-sensitivity C-reactive Protein (mg/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Prothrombin Activity (%) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Albumin (g/dL) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Factor XIV Activity (%) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Tumor Necrosis Factor (pg/mL) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Factor VII Activity (%) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Lambda Light Chain, Free (mg/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Interleukin 6 (pg/mL) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Complement Factor D (mcg/mL) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Kappa Light Chain, Free (mg/L) at End of Study (up to Week 24) Baseline, Week 24
Secondary Change From Baseline in Beta-2 Microglobulin (mg/L) at End of Study (up to Week 24) Baseline, Week 24
See also
  Status Clinical Trial Phase
Completed NCT04076488 - Feasibility of an Interactive Tablet-based Exercise Program for People With Chronical Diseases N/A
Completed NCT03289650 - Extended Release Tacrolimus vs. Twice-Daily Tacrolimus Phase 3
Completed NCT04042324 - A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients Phase 1/Phase 2
Completed NCT01242904 - Use of a Bimodal Solution for Peritoneal Dialysis Phase 2
Active, not recruiting NCT03183245 - Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis Phase 3
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A
Withdrawn NCT02130817 - Belatacept in Kidney Transplantation of Moderately Sensitized Patients Phase 4
Completed NCT05540457 - Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis) N/A
Not yet recruiting NCT04900610 - The Effect of Vitamin K2 Supplementation on Arterial Stifness and Cardiovascular Events in PEritonial DIAlysis N/A
Recruiting NCT02176434 - Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease N/A
Active, not recruiting NCT02581449 - Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis Phase 2
Completed NCT02832466 - Quantifying the Deterioration of Physical Function in Renal Patients N/A
Completed NCT02215655 - Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence N/A
Completed NCT02134314 - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Phase 1/Phase 2
Completed NCT02830490 - Reliability of Functional Measures in Hemodialysis Patient. N/A
Completed NCT02832440 - Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis N/A
Recruiting NCT01912001 - Virtual Ward for Home Dialysis N/A
Completed NCT01951404 - Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Phase 4

External Links